Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Kiora Pharmaceuticals (KPRX) EBIT Margin (2016 - 2024)

Kiora Pharmaceuticals (KPRX) has disclosed EBIT Margin for 8 consecutive years, with 12724.44% as the latest value for Q2 2024.

  • For the quarter ending Q2 2024, EBIT Margin changed N/A year-over-year to 12724.44%, compared with a TTM value of 55210.8% through Mar 2025, down 5522627.0%, and an annual FY2024 reading of 28.15%, changed N/A over the prior year.
  • EBIT Margin was 12724.44% for Q2 2024 at Kiora Pharmaceuticals, down from 82.64% in the prior quarter.
  • Across five years, EBIT Margin topped out at 293029.45% in Q1 2021 and bottomed at 12724.44% in Q2 2024.
  • Average EBIT Margin over 3 years is 93322.73%, with a median of 67571.74% recorded in 2021.
  • Peak annual rise in EBIT Margin hit 16388546bps in 2021, while the deepest fall reached 16388546bps in 2021.
  • Year by year, EBIT Margin stood at 9698.8% in 2020, then surged by 1690bps to 154186.67% in 2021, then plummeted by -108bps to 12724.44% in 2024.
  • Business Quant data shows EBIT Margin for KPRX at 12724.44% in Q2 2024, 82.64% in Q1 2024, and 154186.67% in Q4 2021.